Ficlatuzumab

From WikiMD.org
Jump to navigation Jump to search

Ficlatuzumab

Ficlatuzumab (pronounced as fik-la-too-zoo-mab) is a monoclonal antibody designed for the treatment of various types of cancer. It is a targeted therapy that works by blocking the activity of a specific protein in the body that promotes cancer growth.

Etymology

The name "Ficlatuzumab" is derived from the International Nonproprietary Names (INN), where "-mab" is used for monoclonal antibodies, "tu-" for tumor, "zu-" for humanized, and "ficla-" is a unique stem.

Mechanism of Action

Ficlatuzumab works by targeting and inhibiting the Hepatocyte Growth Factor (HGF)/c-Met pathway, a key process in cancer cell growth and survival. By blocking this pathway, Ficlatuzumab can slow down or stop the growth of cancer cells.

Clinical Trials

Ficlatuzumab is currently in various stages of clinical trials for the treatment of different types of cancer, including head and neck cancer, non-small cell lung cancer, and pancreatic cancer.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski